Investment Rating - The report maintains a "Buy" rating for Angelalign, with an expected target price of HKD 91.89, reflecting a potential upside of 22.8% from the current price of HKD 72.85 [4][6]. Core Insights - Angelalign reported strong fiscal year 2025 results, with revenue increasing by 37.8% year-on-year to USD 370 million and net profit rising by 134.7% to USD 28 million, exceeding estimates by 9% and 140% respectively [1][4]. - The company's total shipment volume grew by 48.1% to 532,400 units, driven by rapid overseas expansion and continued market share growth in the domestic market [1]. - The overseas business remains a key growth driver, with overseas revenue up 102.5% to USD 163 million, and case volume increasing by 82.1% to approximately 256,200 units [2]. - Domestic performance showed resilience, with revenue growing by 10.1% to USD 207 million and case shipment volume increasing by 26.3% to approximately 276,200 units, indicating a more rational competitive landscape [3]. Summary by Sections Financial Performance - For fiscal year 2025, Angelalign's revenue reached USD 370 million, with a year-on-year growth rate of 37.8%. The adjusted net profit was USD 44 million, reflecting a 63.0% increase [5]. - The forecast for fiscal year 2026 anticipates revenue of USD 450 million, representing a 21.4% growth, while adjusted net profit is expected to be USD 56 million, a 28.9% increase [5][11]. Profitability and Margins - The report notes a significant improvement in profitability, with the gross profit margin in the domestic market increasing by 2 percentage points to 65%, offsetting average selling price pressures [3]. - Despite anticipated challenges from global capacity expansion and rising intellectual property litigation costs, the overall profitability is expected to remain strong [1][4]. Valuation Metrics - The report applies a price-to-earnings (P/E) ratio of 18x for the domestic business and a price-to-sales (P/S) ratio of 5x for the faster-growing overseas business, aligning with industry peers [4]. - The target price of HKD 91.89 is derived from a sum-of-the-parts (SOTP) valuation, indicating a robust outlook for both domestic and international operations [10].

Investment Rating - The report upgrades the investment rating of the company to "Buy" from "Hold" [2][4][5] Core Insights - The company has shown improvement in profitability, with a revenue of 6.61 billion RMB in 2025, a year-on-year increase of 1.1%, and a net profit attributable to shareholders of 0.85 billion RMB, up 15.5% year-on-year [4][5] - The second half of 2025 saw revenue and net profit growth rates of 2.0% and 26.3%, respectively, benefiting from enhanced operational efficiency and price adjustments [4][5] - The company is expected to continue its high dividend strategy, with a dividend yield exceeding 6% [5] - Revenue projections for 2026-2028 are set at 7.06 billion, 7.58 billion, and 8.14 billion RMB, with year-on-year growth rates of 6.8%, 7.2%, and 7.5% respectively [5][7] - Net profit forecasts for the same period are 0.96 billion, 1.06 billion, and 1.16 billion RMB, with growth rates of 12.3%, 10.3%, and 9.5% respectively [5][7] Financial Performance Summary - The company’s third-party business revenue reached 4.78 billion RMB in 2025, a year-on-year increase of 4.7%, accounting for 72.3% of total revenue [8] - The company’s gross margin improved to 32.7% in 2025, up 1.5 percentage points year-on-year, driven by optimized production efficiency and reduced raw material costs [8] - The net profit margin for the second half of 2025 increased to 14.8%, reflecting a year-on-year rise of 2.8 percentage points [8] - The company’s revenue from overseas channels grew by 45.4% year-on-year, reaching 0.43 billion RMB in 2025 [8]

Investment Rating - The report maintains a "Buy" rating for Meitu, indicating a positive outlook for the company's performance in the market [5][10]. Core Insights - The company achieved a revenue of HKD 3.86 billion for the fiscal year ending March 2025, representing a year-on-year growth of 28.8% from its continuing operations [10]. - Adjusted net profit for the same period was HKD 965 million, reflecting a significant increase of 64.7% year-on-year, aligning with market expectations [10]. - The company announced a share buyback plan of up to HKD 300 million and a final dividend of HKD 0.05 per share, resulting in a total payout ratio of 40% [10]. - The AI-driven core imaging business saw revenue growth of 42% to HKD 2.95 billion, now accounting for 77% of total revenue from continuing operations [10]. - The number of paying users increased by 34% to 16.91 million, with an improved payment rate of 6.1% [10]. - The company is focusing on productivity and globalization strategies, with a 67% increase in productivity paying users [10]. - The report suggests that the market's negative sentiment regarding competition in large models is overly pessimistic, as Meitu's technology and operational capabilities remain strong [10]. - The adjusted net profit forecasts for 2026 and 2027 have been slightly raised to HKD 13.46 billion and HKD 16.90 billion, respectively, with a new forecast for 2028 set at HKD 20.29 billion [10]. Financial Data and Profit Forecast - Projected revenues for the next five years are as follows: - 2024: HKD 2.996 billion - 2025: HKD 3.859 billion - 2026E: HKD 4.965 billion - 2027E: HKD 5.990 billion - 2028E: HKD 7.025 billion [9][11] - Adjusted net profit projections are: - 2024: HKD 586 million - 2025: HKD 965 million - 2026E: HKD 1.346 billion - 2027E: HKD 1.690 billion - 2028E: HKD 2.029 billion [9][11] - The report indicates a consistent increase in return on equity (ROE), projected to reach 21% by 2027 and 2028 [9].

Investment Rating - The report assigns a "Buy" rating for WuXi XDC (02268.HK) as it is the first coverage of the company [5] Core Views - The XDC industry remains vibrant, with continuous high investment in capacity and leading technology [5] - WuXi XDC is a global leader in bioconjugate drug contract research, development, and manufacturing (CRDMO), with strong revenue growth and profitability [7] - The company has a robust project pipeline and has signed numerous comprehensive projects, indicating strong future growth potential [7] Financial Performance Summary - Revenue projections for WuXi XDC are as follows: - 2024: 4,052 million RMB (90.80% YoY growth) - 2025: 5,944 million RMB (46.69% YoY growth) - 2026E: 8,032 million RMB (35.12% YoY growth) - 2027E: 10,811 million RMB (34.60% YoY growth) - 2028E: 14,139 million RMB (30.78% YoY growth) [6] - Net profit projections are as follows: - 2024: 1,070 million RMB (277.24% YoY growth) - 2025: 1,480 million RMB (38.41% YoY growth) - 2026E: 2,010 million RMB (35.76% YoY growth) - 2027E: 2,859 million RMB (42.26% YoY growth) - 2028E: 3,815 million RMB (33.43% YoY growth) [6] - Earnings per share (EPS) projections are: - 2024: 0.89 RMB - 2025: 1.22 RMB - 2026E: 1.60 RMB - 2027E: 2.27 RMB - 2028E: 3.03 RMB [6] Growth Drivers - The company has a strong order backlog, with an unfulfilled order amount of 1.489 billion USD as of December 31, 2025, reflecting a 50.3% YoY increase [7] - The number of drug discovery phase projects has significantly increased, from 681 projects in 2024 to 1,039 projects in 2025 [7] - WuXi XDC is expanding its global footprint with new production capacities and strategic acquisitions, including the acquisition of Dongyao Pharmaceutical [7]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance in the renewable energy sector is recovering, with a significant increase in wind power generation and profitability, despite challenges in the natural gas business [2][5]. - In 2025, the company achieved a net profit of 1.826 billion yuan, a year-on-year increase of 9.21%, driven by the recovery in the renewable energy sector [2][5]. - The company plans to distribute a cash dividend of 0.2 yuan per share, maintaining a stable dividend policy with a payout ratio of 49.42% [8]. Summary by Relevant Sections Financial Performance - In 2025, the company reported total revenue of 19.831 billion yuan, a decrease of 7.21% year-on-year, while the net profit attributable to shareholders was 1.826 billion yuan, an increase of 9.21% [5]. - The renewable energy segment saw a net profit of 1.612 billion yuan, up 11.95% year-on-year, supported by an increase in wind power generation and improved wind conditions [2][5]. Renewable Energy Segment - The company added 1.2705 million kilowatts of wind power capacity in 2025, bringing the total to 7.778 million kilowatts, a year-on-year increase of 18.07% [8]. - Wind power generation reached 14.85 billion kilowatt-hours, a year-on-year increase of 6.78%, while solar power generation increased by 68.14% [8]. Natural Gas Business - The natural gas segment faced challenges, with total sales volume decreasing by 10.71% to 5.255 billion cubic meters due to weakened market demand [8]. - The net profit from the natural gas business was 358 million yuan, down 25.01% year-on-year, reflecting the adverse industry conditions [2][5]. Strategic Adjustments - The company is divesting its solar power business to focus on its core wind power operations, with plans to gradually sell or transfer existing solar projects [8]. - As of the end of 2025, the company had 1.2981 million kilowatts of wind power capacity under construction, which is expected to enhance future growth [8].

Investment Rating - The investment rating for Geely Automobile is "Buy" and is maintained [7]. Core Insights - Geely Automobile reported a revenue of 345.23 billion yuan for 2025, representing a year-on-year increase of 25.1%. Total sales reached 3.025 million units, up 39.0% year-on-year, with a core net profit attributable to shareholders of 14.41 billion yuan, reflecting a 36% increase year-on-year [2][4]. - The GEA architecture supports the new vehicle cycle, with high-end brands such as Zeekr and Lynk & Co performing well, leading to sustained profit realization. The transition to new energy across brands is progressing smoothly, with scale effects gradually enhancing profitability [2][4]. Summary by Relevant Sections Financial Performance - In Q4 2025, Geely achieved a revenue of 105.76 billion yuan, a year-on-year increase of 45.8% and a quarter-on-quarter increase of 18.6%. Total sales for Q4 were 854,000 units, with significant contributions from the Galaxy, Lynk & Co, and Zeekr brands [7]. - The Q4 net profit attributable to shareholders was 3.74 billion yuan, showing a year-on-year increase of 4.5% but a quarter-on-quarter decrease of 2.0%. The gross margin for Q4 was 16.9%, slightly down by 0.5 percentage points year-on-year but up by 0.3 percentage points quarter-on-quarter [7]. Strategic Focus - Geely's strategy emphasizes electric and intelligent vehicle development, with plans to expand its high-end product matrix. The company aims to achieve total sales of 3.45 million units in 2026, a 14% increase year-on-year, with specific targets for each brand [7]. - The company is accelerating its overseas expansion, targeting major markets in Europe, ASEAN, and Eastern Europe, with plans to increase the number of overseas channels to over 2,200 [7]. Market Position - Geely's market share reached 10.05% in 2025, showing a year-on-year improvement. The average revenue per vehicle in Q4 was 124,000 yuan, up 17.3% year-on-year [7].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][19] Core Views - The company is expected to achieve a total revenue of 6.613 billion yuan in 2025, representing a year-on-year growth of 1.1%, and a net profit attributable to shareholders of 854 million yuan, reflecting a year-on-year increase of 15.5% [7][3] - The company has improved its profitability, with a gross margin increase of 1.4 percentage points to 32.7% in 2025, benefiting from cost reduction and efficiency improvements [10][2] - The company is deepening its overseas channel layout, with third-party overseas channel sales revenue reaching 426 million yuan, a year-on-year growth of 45.4% [12][2] Summary by Sections Revenue and Profitability - In 2025, the company reported total revenue of 66.13 billion yuan, with a net profit of 8.54 billion yuan [7][3] - The revenue from related parties decreased by 7.2% to 18.3 billion yuan, while third-party business revenue increased by 4.7% to 47.8 billion yuan [9][3] - The company’s net profit margin improved to 12.9%, up 1.6 percentage points year-on-year, primarily due to the improvement in gross margin [10][2] Cost Management - The sales expense ratio and management expense ratio were 11.6% and 4.5%, respectively, showing effective cost control [10][2] - The company has implemented a refined operation strategy focusing on the expansion of third-party sales channels [12][2] Future Projections - Revenue forecasts for 2026-2028 are adjusted to 71.0 billion yuan, 76.5 billion yuan, and 81.7 billion yuan, with expected year-on-year growth rates of 7.4%, 7.7%, and 6.8% respectively [3][14] - Net profit forecasts for the same period are adjusted to 9.9 billion yuan, 10.8 billion yuan, and 11.3 billion yuan, with year-on-year growth rates of 16.2%, 8.5%, and 4.9% respectively [3][14] Dividend Policy - The company plans to distribute a total dividend of 784 million yuan in 2025, corresponding to a dividend payout ratio of 91.8% [13][2]

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The company's revenue and profit have shown stable growth, with operating income reaching HKD 77 billion in 2025, a year-on-year increase of 8.1%, and net profit attributable to ordinary shareholders amounting to HKD 40.1 billion, up 4.9% year-on-year [1][3] - The company's asset scale has steadily expanded, with total assets growing by 7.0% year-on-year to HKD 4.49 trillion by the end of 2025 [1] - The net interest margin has decreased to 1.40%, down 6 basis points year-on-year, primarily due to declining market interest rates [2] - Non-interest income has increased significantly, with net fee income rising by 13.9% to HKD 11.3 billion, driven by strong demand in wealth management [2] - Asset quality has shown marginal pressure, with the non-performing loan generation rate increasing to 0.40%, up 0.13 percentage points year-on-year [2] Financial Forecasts and Metrics - The company is expected to achieve net profits of HKD 42.1 billion in 2026 and HKD 44.4 billion in 2027, with corresponding EPS of HKD 3.98 and HKD 4.20 [3][4] - The projected price-to-earnings (PE) ratios for 2026 and 2027 are 10.2 and 9.7, respectively, while the price-to-book (PB) ratios are expected to be 1.13 and 1.07 [3][4] - The return on equity (ROE) is projected to be 11.7% in 2026 and 11.7% in 2027, indicating stable profitability [4][6]

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 19.30 and a fair value of HKD 30.13 [5]. Core Insights - The company has achieved significant growth in 2025, with a revenue of RMB 3.001 billion, representing a year-on-year increase of 16.65%. The net profit reached RMB 340 million, up 34.77%, and the attributable net profit was RMB 318 million, reflecting a 39.00% increase. The adjusted net profit was RMB 381 million, showing a growth of 40.97% [8]. - The strong performance is attributed to accelerated external expansion, including the acquisition of the Nair brand, which enhances market share, and sustained organic growth driven by high-margin business segments [8]. - The company operates three main business segments: beauty and health services, medical beauty services, and sub-health medical services, all of which have shown growth in revenue and profitability [8]. Financial Summary - Revenue projections for 2024 to 2028 are as follows: RMB 2.572 billion (2024), RMB 3.001 billion (2025), RMB 4.013 billion (2026), RMB 4.786 billion (2027), and RMB 5.644 billion (2028), with growth rates of 19.9%, 16.7%, 33.7%, 19.3%, and 17.9% respectively [4][12]. - The company's EBITDA is projected to grow from RMB 704 million in 2024 to RMB 1.311 billion in 2028, with a notable increase in net profit from RMB 228 million in 2024 to RMB 651 million in 2028 [4][12]. - The report highlights a significant improvement in profitability metrics, with ROE expected to rise from 24.2% in 2024 to 35.8% in 2028 [4][12]. Business Performance - The beauty and health services segment generated RMB 1.658 billion in 2025, up 14.88%, while medical beauty services and sub-health medical services achieved revenues of RMB 1.017 billion and RMB 326 million, respectively, with growth rates of 9.56% and 62.16% [8]. - The gross margins for these segments were reported at 41.88%, 55.87%, and 64.31%, respectively, indicating an upward trend in profitability [8]. Strategic Outlook - The company is positioned as a leader in the industry, with a strong brand portfolio including Meili Tianyuan, Nair, and Siyuanli, which collectively enhance its competitive advantage [8]. - The dual strategy of organic growth and external acquisitions is expected to drive sustained high growth in the coming years, supported by refined operational efficiencies and scale effects [8].

Investment Rating - The report maintains a "Buy" rating for the company, Kolun Botai Biopharmaceutical-B (06990) [1][9] Core Insights - Kolun Botai's core product, sac-TMT (Lukangshatuozhuzhujun), has accelerated commercialization with multiple indications approved by NMPA, including breast cancer and lung cancer treatments [5][6] - The company reported a revenue of 2.058 billion yuan for 2025, a year-on-year increase of 6.5%, with a significant increase in drug sales revenue by 949.4% [4][9] - The company has established a mature commercialization team of over 600 people, covering 30 provinces and more than 1,200 hospitals, indicating strong market penetration [5][6] Financial Performance - The company experienced a net loss of 382 million yuan in 2025, with adjusted losses of 211 million yuan, primarily due to increased R&D expenses and a decline in licensing and collaboration revenue [4][9] - The gross profit for 2025 was 1.479 billion yuan, with a gross margin of 71.9%, reflecting a 6 percentage point increase year-on-year [4][9] - Cash and financial assets reached 4.559 billion yuan, a year-on-year increase of 48.2% [4] Revenue Forecast - Projected revenues for 2026, 2027, and 2028 are 2.377 billion yuan, 3.299 billion yuan, and 6.016 billion yuan, respectively, with growth rates of 16%, 39%, and 82% [9][10] - The company anticipates a return to profitability by 2027, with a projected net profit of 296 million yuan and a significant increase to 1.201 billion yuan by 2028 [10][11] Clinical Development - sac-TMT is involved in 17 global Phase 3 clinical trials, targeting various cancers, with promising data expected to be released soon [6][7] - The drug has shown superior efficacy in clinical trials, with an objective response rate of 45.1% compared to 15.6% for chemotherapy in patients with EGFR-TKI and platinum-based chemotherapy failures [7]